Dual color chromogenic in situ hybridization for determination of HER2 status in breast cancer: A large comparative study to current state of the art fluorescence in situ hybridization

BMC Clinical Pathology

Volumn 12, Issue , 2012, Pages

  Mollerup, Jens ^a   Henriksen, Ulla ^a   Müller, Sven ^a   Schønau, Andreas ^a  

^a AGILENT TECHNOLOGIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ARTICLE; BREAST CANCER; CANCER TISSUE; CHROMOGENIC IN SITU HYBRIDIZATION; CISH PHARMDX KIT; FISH PHARMDX KIT; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; HUMAN; HUMAN TISSUE; HYBRIDIZATION; INTERMETHOD COMPARISON; MEDICAL DEVICE; PATHVYSION HER-2 DNA PROBE KIT;

EID: 84857019105     PISSN: None     EISSN: 14726890     Source Type: Journal    
DOI: 10.1186/1472-6890-12-3     Document Type: Article

References (19)

1. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN, Oncologist 2009 14 4 320 368 10.1634/theoncologist. 2008-0230 19346299
2. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL, Science 1987 235 4785 177 182 10.1126/science.3798106 3798106 (Pubitemid 17231334)
3. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Ross JS, Fletcher JA, Stem Cells 1998 16 6 413 428 10.1002/stem.160413 9831867 (Pubitemid 28524507)
4. ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Kallioniemi OP, Kallioniemi A, Kurisu W, Thor A, Chen LC, Smith HS, Waldman FM, Pinkel D, Gray JW, Proc Natl Acad Sci USA 1992 89 12 5321 5325 10.1073/pnas.89.12.5321 1351679
5. Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Tanner M, Gancberg D, Di LA, Larsimont D, Rouas G, Piccart MJ, Isola J, Am J Pathol 2000 157 5 1467 1472 10.1016/S0002-9440(10) 64785-2 11073807
6. Chromogenic in situ hybridization for the detection of HER-2/neu gene amplification in breast cancer with an emphasis on tumors with borderline and low-level amplification: does it measure up to fluorescence in situ hybridization? Bhargava R, Lal P, Chen B, Am J Clin Pathol 2005 123 2 237 243 10.1309/C4PEBGB9LN830TVL 15842048 (Pubitemid 40194085)
7. Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer. Arnould L, Denoux Y, MacGrogan G, Penault-Llorca F, Fiche M, Treilleux I, Mathieu MC, Vincent-Salomon A, Vilain MO, Couturier J, Br J Cancer 2003 88 10 1587 1591 10.1038/sj.bjc.6600943 12771927 (Pubitemid 36713787)
8. Chromogenic and fluorescent in situ hybridization in breast cancer. Lambros MB, Natrajan R, Reis-Filho JS, Hum Pathol 2007 38 8 1105 1122 10.1016/j.humpath.2007.04.011 17640550 (Pubitemid 47058171)
9. Targeted therapy in breast cancer: the HER-2/neu gene and protein. Ross JS, Fletcher JA, Bloom KJ, Linette GP, Stec J, Symmans WF, Pusztai L, Hortobagyi GN, Molecular Cell Proteomics 2004 3 4 379 398 10.1074/mcp.R400001-MCP200 (Pubitemid 38702091)
10. "CISH the FISH" for HER2: our laboratory experience. Arena V, Pennacchia I, Vecchio FM, Carbone A, Am J Clin Pathol 2010 134 2 347 348 10.1309/AJCPVH1IGEG8CPXB 20660343
11. Interval Estimation for a Binomial Proportion. Brown LD, Cai T, DasGupta A, Stat Sci 2001 16 2 101 133 (Pubitemid 33636344)
12. Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis. Dendukuri N, Khetani K, McIsaac M, Brophy J, CMAJ 2007 176 10 1429 1434 10.1503/cmaj.061011 17485695 (Pubitemid 46762020)
13. A Coefficient of Agreement for Nominal Scales. Cohen J, Educ Psychol Meas 1960 20 1 37 46 10.1177/001316446002000104
14. Matchmaking and McNemar in the comparison of diagnostic modalities. Dwyer AJ, Radiology 1991 178 2 328 330 1987587
15. Determination of HER2 amplification in primary breast cancer using dual-color chromogenic in situ hybridization is comparable to fluorescence in situ hybridization: a European multicenter study involving 168 specimens. García-Caballero T, Grabau D, Green AR, Gregory J, Schad A, Kohlwes E, Ellis IO, Watts S, Mollerup J, Histopathology 2010 56 472 480 10.1111/j.1365-2559.2010.03503.x 20459554
16. The correlation between dual-color chromogenic in situ hybridization and fluorescence in situ hybridization in assessing HER2 gene amplification in breast cancer. Pedersen M, Rasmussen BB, Diagn Mol Pathol 2009 18 2 96 102 10.1097/PDM.0b013e31817f5227 19430295
17. Visualization of FISH Probes by dual-color chromogenic in situ hybridization. Hoff K, Jorgensen JT, Muller S, Rongaard E, Rasmussen O, Schonau A, Am J Clin Pathol 2009 133 2 205 211
18. Evaluation of HER2 gene amplification in invasive breast cancer using a dual-color chromogenic in situ hybridization (dual CISH). Kato N, Itoh H, Serizawa A, Hatanaka Y, Umemura S, Osamura RY, Pathol Int 2010 60 7 510 515 10.1111/j.1440-1827.2010.02553.x 20594272
19. Chromogenic in situ hybridization: a novel approach to a practical and sensitive method for the detection of HER2 oncogene in archival human breast carcinoma. Dandachi N, Dietze O, Hauser-Kronberger C, Lab Invest 2002 82 8 1007 1014 12177239